SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX -- Ignore unavailable to you. Want to Upgrade?


To: cheeseboy who wrote (440)3/14/1998 1:15:00 PM
From: ajs  Respond to of 1754
 
Cheesboy, Thanks for your insight, where was it 2 years ago !

You make number of good points, however is it at all possible that both Summit & Visx can be profitable investments with the aniticipated growth in LVC ? Whether they act like it or not they are essentially partners with PPP.

Also although you state BEAM does not have enough cash for an aquistion BEAM openly states they are actively seeking a partner. If this happens, (& I assume Visx will aquire another company as well) This will again start another round of debates regarding technology and VISX may find it's self in an equal or inferior position to BEAM.

- Beam is actively attemting to close the "Lasik Loophole" It won't be open forever.

- Beam has new a management team with close ties to B&L and may be aquired by them at some point as well.

In closing, this technology is great & both machines are effective, if this market is as big as we all hope it is there should be room for 2 or more companies. In the words of Rodney King "Can't we all just get along ?"

I realize an investment in BEAM carries a significant more amount of risk than a similar investment in VISX, however I think Beam's stock may still be able recover somewhat and participate in the increased popularity of this procedure. I would buy more VISX as well but am a little wary at these levles.



To: cheeseboy who wrote (440)3/14/1998 1:23:00 PM
From: pappy  Respond to of 1754
 
HEY CHEESIE:

How come the difference at these sites for SUMMIT and VISX. YEAH, I know, they don't know what their talking about..only you do!!!!

thomsoninvest.net

thomsoninvest.net

Also, you tend to bore...



To: cheeseboy who wrote (440)3/14/1998 4:31:00 PM
From: yosid  Read Replies (1) | Respond to of 1754
 
Mr. Cheese
Let me take this opportunity to thank you for your profound insights.
It is so infrequent that the great "unwashed" gets the chance to sit at the knee of a true Stock Profit. You have created a true dilemma today. I can't decide if I will peruse Barons, your Research commentary, or the Bible.
Please forgive our Dick and Jane approach to stock investing. We so seldom take the time to read, and Surely what we do could never be construed as "research". Oh God, if I could only drive this Peasant out of me! No, I guess not. I guess we will continue as always:
We buy. We sell. We go long. We go short.
And at the end of the day, we wash our feet.



To: cheeseboy who wrote (440)3/14/1998 11:25:00 PM
From: Vector1  Read Replies (1) | Respond to of 1754
 
Cheeseboy,
Excellent post. An number of institutional investors are beginning to follow the sequential quarterly revenue growth at the larger vision centers. This is probably the single largest reason for VISX's run the Paine Webber report notwithstanding. PW has has a strong buy out on the company for some time and Charles O has written numerous positive reports. When the stock was trading in the high teens he was as perplexed as everyone else.
In many respects VISX has been tarnished by the battles with Summit. Frankly, other than the lawsuit Summit is largely irrelevent. Laser eye surgery is here to stay and VISX is the best capitalized company, has a significant installed base and professional management. I think it is likely that we will see 50 before year end.
V1



To: cheeseboy who wrote (440)3/14/1998 11:56:00 PM
From: Vector1  Read Replies (2) | Respond to of 1754
 
Paine Webber issued another report on VISX on Fri afternoon. I am not sure if it was before or after the market close. In summary they affirmed their strong buy, raised their price target to $40 per share and provided a new estimate for the year at $1.65 per share. The report further stated that based upon the strength in jan and Feb the $1.65 could well be conservative.
V1